ecancer 2013, 7:379 DOI: 10.3332/ecancer.2013.379 Epithelial tumours of the ovary can be either benign (cystadenomas) or malignant (cystadenocarcinomas). However, there is an intermediate state of epithelial tumours of the ovary called ‘borderline tumours’. Neither the oncological behaviour of this intermediate group of tumours nor the histological changes of the cells of the ovarian epithelium meet the specific... Continue Reading →
VERY helpful Cochrane review re. treatment of BOTs. Why is it helpful? While clear guidelines are often available for the management of ovarian cancer, less clear guidelines exist for the management of the rarer, less lethal and less researched borderline ovarian tumours (FIGO 2006). Consequently, our aim is to review the available evidence from studies... Continue Reading →
Very helpful Cochrane Review: Interventions for the treatment of borderline ovarian tumours
I’ve created a dropbox folder where I’m uploading documents that may be of interest/helpful that relate to BOTs.Borderline Ovarian Tumours: documents of interest
Borderline Ovarian Tumours: documents of interest
An event in Glasgow brought together women with ovarian cancer, GPs and health educators to launch Target Ovarian Cancer’s new ovarian cancer toolkit for GPs. Hoping that it’s possible to view a copy of the tool kit… probably some very helpful information for providers and patients alike.New ovarian cancer toolkit launched for GPs in Scotland... Continue Reading →
New ovarian cancer toolkit launched for GPs in Scotland | Target Ovarian Cancer
The Naming Debate: to BOT or not?
The Naming Debate results in such confusion. BOTs or *insert name of choice* seem to have failed any attempt at standard naming. The Atlantic Ocean appears to offer a fault line between the major Naming Debate Contenders. In an uninformed nutshell, it appears that the Anglo-side prefer BOT - borderline ovarian tumour - which emphasises tumour, whilst... Continue Reading →
I was again reminded of this article: long but excellent. Abstract: Borderline ovarian tumors represent a heterogeneous group of noninvasive tumors of uncertain malignant potential with characteristic histology. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic recurrence and death may be found as long as... Continue Reading →
Diagnosis, treatment, and follow-up of borderline ovarian tumors
Video that I have just come across (thank you Nicky!) explaining a histologist’s view of a borderline ovarian tumour. (He starts with a reminder of Madonna’s hit, Borderline, obviously).(Source: https://www.youtube.com/)
Staging of BOTs
Staging and grading assists in determining treatment plans moving forward. It is only at this point that the difference between OC and a BOT will be determined.This happens post-operatively as the tumour and anything else removed - e.g. ovary/ovaries, fallopian tube/s, uterus, omentum, fluid from your abdominal cavity - will be analysed under the microscope.... Continue Reading →
BOTs are APOTs.
Given the confusion that I already have, imagine my delight at discovering yet another acronym: APOT. Apparently, this is an Atypical Proliferative Ovarian Tumour; otherwise known as BOT (so, they’re the same thing). At least the piece where I discovered APOTs clearly indicates exactly what my consultant emphasised: At the present time, the use of the... Continue Reading →
“What’s in a name? In terms of borderline tumors? A lot!” – Mario M. Leitao, Jr
I have been chatting with another BOT-lady and have realised - once again - how confusing the language used to describe BOTS (and, from what I can tell, all tumours, ovarian or otherwise) are. As mentioned in previous posts, the naming of BOTS remains controversial (amongst some). A scan of some of the literature and... Continue Reading →
jozi-ovari 